cyrilzakka/clinical-trials huggingface dataset:
Theta Burst Stimulation for Compulsive Behavior Non-invasive Brain Stimulation Study

This project seeks to identify causal neural mechanisms underlying unwanted, repetitive behaviors (compulsions). Using non-invasive brain stimulation coupled with practice in a computer task, we will modulate activity in a target brain region in two directions (up or down) and measure effects on compulsive behaviors and related measures. This work could ultimately lead to the ability to treat compulsions more effectively by targeting the regions of the brain that can help or hinder attempts to overcome compulsions.


Eligibility Criteria:
Inclusion Criteria:

Participants will:

1. Be between the ages of 18 and 55 years
2. Endorse problematic compulsive behaviors, per self-report and clinician-administered measures.
3. Agree to video taping of structured clinical interview
4. Report that they will reside in the Pittsburgh area for at least 5 weeks

Exclusion Criteria:

1. Failure to meet standard MRI inclusion criteria: those who endorse claustrophobia, those who have cardiac pacemakers, neural pacemakers, surgical clips in the brain or blood vessels, surgically implanted metal plates, screws or pins, cochlear implants, implanted uterine devices, metal braces, or other metal objects in their body, especially in the eye. Dental fillings do not present a problem. Plastic or removable dental appliances do not require exclusion. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results. Pregnancy, determined by pregnancy tests on females.
2. Medical contraindications for Transcranial Magnetic Stimulation (TMS):

   1. Presence of a neurologic disorder or medication therapy known to alter seizure threshold (e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches)
   2. Recurrent seizures or epilepsy in participant or family history of hereditary epilepsy
   3. Pregnancy
   4. Metallic implants in body or other devices that may be affected by magnetic field
   5. Significant heart disease or cerebrovascular disease
   6. Medications with seizure threshold lowering potential, e.g., clomipramine, Monoamine Oxidase inhibitors (MAOi's), imipramine, clozapine
3. Acute suicidality or other psychiatric crises requiring treatment escalation
4. Changes made to treatment regimen within 4 weeks of baseline assessment
5. Reading level \<6th grade
6. Presence of bipolar, psychotic, autism spectrum, or substance use disorder (i.e. current use of mood altering drugs such as cocaine, cannabis or marijuana, opiates, amphetamines, and barbiturates)
7. Presence of movement disorder or tics affecting manual responses
8. Inability to read text from 2 feet away (corrective lenses allowed)
Biomarkers to Detect Endocrine Therapy Resistance

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.


Eligibility Criteria:
Inclusion Criteria:

1. Willing to provide informed consent
2. Individuals at least 18 years of age
3. Have biopsy-proven ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new standard of care endocrine therapy
4. Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist
5. Patients with evaluable bone-only disease that is lytic or mixed lytic-sclerotic are eligible
6. Willing to comply with all study procedures and be available for the duration of the study
7. Disease may be measurable by RECIST 1.1 criteria or non-measurable. Lesion size must be at least 1cm. If only bone lesions present, they should be lytic or mixed lytic-sclerotic. If only liver lesions present, patient is not eligible.

Exclusion Criteria:

1. Patients with active brain metastases
2. Patients with liver-only disease are not eligible due to high background liver activity related to the radiopharmaceutical's hepatobiliary route of elimination
3. Unable to lie flat during or tolerate PET/CT
4. Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
5. Presence of liver failure as judged by patient's treating physician
6. Individuals who are pregnant, lactating, or planning on becoming pregnant during the study
7. Not suitable for study participation due to other reasons at the discretion of the investigators
8. Patients with progesterone-receptor negative disease defined as PR \<1 percent by IHC
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

The purpose of this study was to compare the efficacy and safety of nafamostat mesylate and unfractionated heparin during ECMO anticoagulation in critically ill patients.

During ECMO treatment, nafamostat mesylate and unfractionated heparin were randomly administered for continuous anticoagulation, respectively, and the incidence of bleeding and thrombotic complications during anticoagulation was compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged \>= 18 and \<= 80 years;
* Successfully established ECMO (VA/VV) treatment by percutaneous puncture due to cardiogenic shock or respiratory failure;
* Anticoagulation required during ECMO treatment; Before the establishment of ECMO, the APTT test value was within the normal range, and the platelets were not less than 80G/L;
* Within 48 hours of ECMO establishment, APTT test results were between 1 and 1.75 times the upper limit of normal, PLT\>80 G/L, and no serious bleeding and thrombosis;
* Sign the informed consent.

Exclusion Criteria:

* Pregnant;
* Bleeding risk or active bleeding;
* Pre-existing diseases requiring long-term anticoagulation before ECMO: pulmonary embolism, deep vein thrombosis, intraventricular thrombosis, atrial fibrillation, etc.;
* Long-term use of anticoagulants before ECMO;
* Antiplatelet drugs were used before ECMO;
* Allergy to heparin, nafamostat mesylate;
* Repeated puncture at the same site for more than 3 times;
* Expected ECMO treatment time \< 3 days;
* Patients with an expected survival period of less than 48 hours;
* Patients undergoing extracorporeal cardiopulmonary resuscitation;
* Burn patients; Blood purification treatment using polyacrylonitrile membrane filter;
* Heterozygous ECMO mode or ECMO therapy solely for CO2 removal;
* Other reasons that the investigator considers inappropriate for inclusion;
Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers

The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.


Eligibility Criteria:
* Inclusion Criteria:

  * Healthy and male subjects aged 20 to 55 years
  * The subject has a Body weight ≥55 kg and ideal body weight (IBW) within ±20%
  * A Subject who was judged to be healthy by the investigator to participate in this study based on screening results (according to standard reference index updated recently)
  * A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints.
* Exclusion Criteria:

  * A subject with sign or symptoms or previously diagnosed disease of respiratory, cardiovascular, endocrinology, liver, kidney, hematology, neurology and psychology function or other significant diseases and history
  * Known allergy or hypersensitivity to the study medication
  * AST or ALT greater than 1.25 times the upper limit of reference range or Total bilirubin greater than 1.25 times the upper limit of reference range base on screening results
  * A subject judged ineligible by the investigator to participate in this study for other reason containing clinical laboratory tests
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan


Eligibility Criteria:
Inclusion Criteria:

* infection due to methicillin-resistant Staphylococcus aureus

Exclusion Criteria:

* hypersensitivity to linezolid
Influence of Resin Cement Composition on the Longevity of Intraradicular Post of Endodontically Treated Teeth

The aim of this study is through a randomized clinical trial, double blind, splithmouth, evaluate the success rate (post or dental crown displacement; fracture of the core/post/crown; marginal integrity and absence of endotontic alterations) of definitive indirect crowns un endodontically treated teeth. The composition of the resin cement (with and without mineral trioxide aggregate) will be evaluated. Data will be collected, tabulated and submitted to statistical analysis.

Endodontically treated teeth present an increased risk of fracture and are usually related to extensive carious processes or trauma that promote major coronary destruction. In such situations, it may be necessary to indicate intra-radicular retainers, such as fiberglass pins, to retain the restorative material. The aim of this study is through a randomized clinical trial, double blind, splithmouth, evaluate the success rate (post or dental crown displacement; fracture of the core/post/crown; marginal integrity and absence of endotontic alterations) of definitive indirect crowns un endodontically treated teeth. The composition of the resin cement (with and without mineral trioxide aggregate) will be evaluated. Twenty participants with at least two teeth with endodontic treatment with need intraradicular post cementation and confection of indirect dental crown (each participant) will be selected. The teeth will be randomly divided into 2 different groups according to resin cement composition (with and without mineral trioxide aggregate). Data will be collected, tabulated and submitted to statistical analysis.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers;
* Presence of at least two teeth with endodontc treatment;
* Presence of at least two teeth with indication of total crowns;
* Good oral hygiene.

Exclusion Criteria:

* Dentures or orthodontics;
* Presence of periodontal disease
* Presence of parafunctional habits
* Presence of systemic disease
* Constant use of analgesic and or anti-inflammatory
* Allergic response to dental products
Evaluation of Muscle Thickness and Balance in Young and Older Adults

This study evaluates muscle thickness of trunk and lower limb and balance in young and older healthy adults. The participants will be evaluated muscle thickness for 14 different muscle and balance which evaluated by computerized force plate system.

Aging had an adverse affect on musculoskeletal system and balance parameters. Decreased muscle strength or thickness negatively affect person's balance control. But there are no information in the literature about the relationships between muscle thickness and balance in healthy subjects. In addition to, it is not known which muscle responsible for balance. Therefore, this study will evaluate muscle thickness via ultrasonography and balance in young and older adults. Balance will be evaluated computerized Balance system. Muscle thickness for different 14 muscle ( diaphragm, transversus abdominis,multifidus, longissimus, quadratus lumborum, rectus abdominis, external and internal obliques, rectus femoris, vastus intermedius, vastus lateralis, tibialis anterior, gastrocnemius, soleus) will be evaluated by ultrasonography at the right side. Only diaphram muscle will be evaluated both right and left side.

Eligibility Criteria:
Inclusion Criteria For Young Adults:

* To be a volunteer to participate
* to be an aged 18-40 years old.

Inclusion Criteria For Older Adults:

* To be a volunteer to participate
* to be an aged 65-90 years old.

Exclusion Criteria:

* Walking with assist device
* Having a visual deficits
* Having an orthopedic problems that affect balance
* Having a neurological disorders
* Having a musculoskeletal disorders that affect balance
* Having an undergone orthopedic surgery
Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score

Prospective, interventional multicentric study in ICU during weaning from mechanical ventilation in tracheotomized patients

Prospective multicentric study on ICU evaluating Lung Ultrasound Score in tracheotomized patients during weaning from mechanical ventilation

Eligibility Criteria:
Inclusion Criteria:

* Adult patients tracheotomised during ICU stay
* Consent of patients

Exclusion Criteria:

* Tracheotomy before ICU
* No echogenicity
Prevalence of Internet Addiction Among Adolescent

Internet is now a tool available 24 hours a day, at a lower cost and accessible almost anywhere. Internet addiction could be defined as the inability to control one's Internet use and the continuation of this behavior despite the occurrence of negative consequences.

Adolescence is a time of vulnerability to addiction, due to social and neurobiological factors.

The aim of the study is to evaluate prevalence of internet addiction among adolescent attending high school

Eligibility Criteria:
Inclusion Criteria:

* adolescent attending high school
* agreeing to participate in the study

Exclusion Criteria:

* None
To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

A multi-center, randomized, double-blind, comparative study to evaluate the clinical efficacy and safety of QL1206 and Xgeva® in patients with bone metastases from solid tumors.

This is A multi-center, randomized, double-blind, comparative clinical trial.

The primary objective is to evaluate whether the clinical efficacy of QL1206 and Xgeva® are similar in patients with bone metastases from solid tumors.

The secondary objective are to evaluate whether the clinical safety and immunogenicity of QL1206 and Xgeva® are similar in patients with bone metastases from solid tumors.

Eligibility Criteria:
Inclusion Criteria:

1. Through the explanation of the researcher or the researcher's authorized representative, the subject has understood the nature and purpose of the study, as well as the research procedure, and the subject has signed the written informed consent;
2. Radiologic evidence (i.e. X-ray examination, computed tomography CT, magnetic resonance imaging MRI, positron emission computed tomography PET-CT) in grade III grade A hospitals has been documented (within 3 months prior to study administration) that there is at least one bone metastasis;
3. The ECOG score was 0-2.
4. Chinese adults with solid tumor confirmed by histological or cytological examination (age ≥18 years, ≤80 years).

Exclusion Criteria:

1. Patients who had received any kind of intravenous or oral bisphosphonates before administration of the first study drug (those who had previously used an intravenous or oral bisphosphonates but had a continuous use time of less than 3 months and more than 5 years before the administration of this study could be included in the study).
2. Previous treatment with denosumab.
3. Previous or ongoing osteomyelitis or osteonecrosis of the jaw ONJ , active dental disease or jaw bone disease requiring oral surgery, the wound of dental operation or oral surgery has not healed well, or invasive dental operation has been planned during the study period.
4. Plan to perform radiotherapy or or bone surgery. Patients who received radiotherapy within one month before the first study drug administration were not allowed to be included.
A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease

Potentially inappropriate prescribing includes the use of medications that may no longer be necessary or that may increase the risk of harm. Inappropriate prescribing can increase the overall symptom burden, and negatively affect health-related quality of life and function. The inappropriate prescription of certain drug categories such as sedative/hypnotics, antipsychotics, and strong anticholinergic agents poses particular risks for older adults, and may be more common among those with Alzheimer's disease and Alzheimer's disease- related dementias (AD/ADRD) due to a higher prevalence of multimorbidity and more frequent prescription of five or more medications. The D-PRESCRIBE-AD (Developing a PRogram to Educate and Sensitize Caregivers to Reduce the Inappropriate Prescription Burden in Elderly with Alzheimer's Disease) study will test a health plan-based intervention using the NIH Collaboratory's Distributed Research Network, which employs the Food and Drug Administration (FDA) Sentinel System infrastructure. The overarching goal of this randomized controlled trial is to assess the effect of a patient/caregiver- centered, multifaceted educational intervention on potentially inappropriate prescribing in patients with AD/ADRD. The research hypothesis is that education on inappropriate prescribing among patients/caregivers and their providers can reduce medication-related morbidity in patients with AD/ADRD and improve medication safety for this vulnerable population. The study population will include community-dwelling patients with AD/ADRD, identified based on diagnoses codes of AD/ADRD or use of a medication for Alzheimer's Disease, who have evidence of potentially inappropriate prescribing the three drug classes above. The trial will evaluate the effect of educational interventions designed to spur patient/caregiver-provider communication about medication safety (versus usual care) on the proportion of patients with inappropriate prescribing, the primary outcome of this study. The trial will be conducted in two large, national health plans.


Eligibility Criteria:
Patient Inclusion Criteria:

1. Diagnosis of AD/ADRD based on a combination of AD/ADRD codes or treatment with a pharmacologic therapy used for AD (e.g., donepezil, rivastigmine, galantamine, and memantine) in the 365 days prior to or on cohort entry date.
2. Evidence of potentially inappropriate prescribing with antipsychotics, sedative-hypnotics, and strong anticholinergics within the past 3 months
3. Age ≥50 years of age as of cohort entry date
4. Continuous medical and pharmacy insurance coverage for at least the prior year

Patient Exclusion Criteria:

1. Evidence of residing in a nursing home or skilled nursing facility or receiving palliative care.
2. Incomplete/missing prescriber ID or incomplete contact information for either patient or prescribing provider.
3. On "do not contact" list
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* histologically confirmed squamous cancer of nasal cavity and paranasal sinuses
* T4bN0-3M0 (AJCC8th) or unresectable lymph nodes or refusal of surgery
* KPS≥70
* NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L
* ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN
* creatinine clearance rate ≥ 60 ml/min (calculated by Cockcroft-Gault)

Exclusion Criteria:

* older than 65 or younger than 18
* HBsAg (+) and HBV DNA \>1×10E3 copiers /mL
* HCV (+)
* HIV (+)
* autoimmune diseases
* interstitial lung diseases
* had other cancers before
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Eligibility Criteria:
Inclusion Criteria:

* Chronic multiple cutaneous

Exclusion Criteria:

* Hypersensitivity to Candida antigen
* Fever
* Immunosuppressive disorders
* Previous wart therapy in the last month
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

This study evaluates the effect of sofosbuvir/ledipasvir (SOF/LDV) treatment on the pharmacokinetics (PK) and renal safety of tenofovir. Subjects receiving tenofovir-based antiretroviral therapy with human immunodeficiency virus (HIV) protease inhibitors (HIV PI/r) and initiating SOF/LDV treatment for Hepatitis C virus (HCV) will be invited to participate. The study consists of three visits: a screening visit and two abbreviated 4-hour pharmacokinetic visits (one before initiating SOF/LDV and a second approximately 4 weeks after initiating SOF/LDV).


Eligibility Criteria:
Inclusion Criteria:

* On tenofovir and a ritonavir-boosted PI for at least 30 days initiating HCV treatment with SOF/LDV
* HCV RNA \<48 copies/mL at most recent clinic visit

Exclusion Criteria:

* eGFR \< 60 ml/min
* history of renal disease
* Pregnant or planning pregnancy
* Any medical, social, or mental-health issue(s) that, in the opinion of the investigators, could interfere with study participation or the study outcomes
The Effect of a Web-Based Breastfeeding Education Program for Adolescent Pregnant

It is crucial to prepare adolescent mothers-who represent a vulnerable group where the importance of breastfeeding is increasingly emphasized-for the breastfeeding process. One potential method for promoting breastfeeding is through web-based education interventions. The aim of this study was to evaluate the effect of a web-based breastfeeding education program, developed by the researchers, on breastfeeding outcomes among adolescent pregnant women in the postpartum period. This randomized controlled study involved a sample of 100 pregnant adolescents, aged 15-19 years, who were in their third trimester of pregnancy. The study commenced after obtaining ethical approval and permissions from the hospital where the research was conducted.

A web-based breastfeeding education program was administered to the experimental group. Data were collected using a Socio-Demographic Data Form, the Breastfeeding Self-Efficacy Scale Short Form (Antenatal Version), the Breastfeeding Self-Efficacy Scale Short Form (Postnatal Version), and the LATCH Breastfeeding Diagnosis and Assessment Scale. Data collection occurred during the third trimester (pretest) and the 1st and 8th postnatal weeks (posttest).


Eligibility Criteria:
Inclusion Criteria:

* Aged between 15 and 19 years
* Had not previously received planned breastfeeding education
* Were between 28 and 37 weeks gestation (third trimester)
* Gave birth at term
* Had no health issues preventing breastfeeding
* Could read, write, and respond to questions
* Had access to a computer, tablet, or smartphone, and had regular internet access.

Exclusion Criteria:

* Participants were excluded if they had multiple pregnancies
* Physical or mental health problems, communication disabilities
* A history of breast surgery
* İf their newborns were considered high-risk.